Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $33.56
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 19, 26 | JP Morgan |
| Overweight |
| Overweight |
| Aug 13, 26 | Citigroup | maintain | Buy | Buy |
| Jul 10, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| May 26, 26 | JP Morgan | maintain | Overweight | Overweight |
| May 11, 26 | Raymond James | downgrade | Outperform | Market Perform |
| Mar 9, 26 | RBC Capital | maintain | Outperform | Outperform |
| Feb 23, 26 | Citigroup | maintain | Buy | Buy |
| Feb 12, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Jan 7, 26 | Citigroup | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 42.91 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 48.72 | Oscillator | Neutral |
| Williams %R (14) | -34.07 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.64 (Hist 0.06) | Oscillator | Buy |
| Average Directional Index (14) | 29.54 (+DI 14.1 / -DI 28.4) | Trend | Strong Sell |
| EMA 20 | 33.85 | MA | Sell |
| SMA 20 | 33.65 | MA | Sell |
| EMA 50 | 35.09 | MA | Strong Sell |
| SMA 50 | 35.36 | MA | Strong Sell |
| SMA 200 | 43.11 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | AD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 3.7x | 3.5x · sector 19.3x | Discount |
| Forward P/E (FY26E) | 5.0x | EPS est. 6.69 | Elevated |
| Price / Book | 2.3x | 0.9x | Elevated |
| Price / Sales | 13.6x | 6.3x | Elevated |
| EV / EBITDA | 4.1x | 11.9x | Discount |
| Return on equity | 37.9% | — | Top tier |
| Gross margin | 41.1% | 48.1% | In line |
| Debt / Equity | 0.95 | 0.82 | Moderate |
| Piotroski / Altman Z | 3/9 | Z 1.48 | Distress |
Discounted cash flow model
Stock news · updated daily
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
[url="]Zai Lab Limited[/url] (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company's internally dev
PHILADELPHIA, Oct. 9, 2026 /PRNewswire/ -- Kaskela Law announces that it is investigating Array Digital Infrastructure, Inc. (NYSE: AD) ("Array Digital") on behalf of the company's shareholders. Register here for additional information: https://kaskelalaw.com/case/array-digital/ Year to date, shares of Array Digital's common stock have generated an investment return of negative 38% , as compared to the S&P 500's investment return of approximately 13% over that same time period.
Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple I
Array Digital Infrastructure Inc. (NYSE: AD - Get Free Report) hit a new 52-week low during mid-day trading on Monday. The company traded as low as $33.70 and last traded at $33.6640, with a volume of 37207 shares. The stock had previously closed at $34.49. Wall Street Analyst Weigh In A number of research firms have
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026PR
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 7, 2026 | 0.41 | 4.15 | Beat 912.9% | $54.07M |
| May 8, 2026 | 0.91 | 2.08 | Beat 127.8% | $52.01M |
| Feb 20, 2026 | 0.32 | 0.48 | Beat 50.0% | $60.33M |
| Nov 7, 2025 | 0.25 | 0.97 | Beat 288.0% | $47.12M |
| Aug 11, 2025 | 0.33 | 0.36 | Beat 9.1% | $916.0M |
| May 2, 2025 | 0.37 | 0.21 | Miss -43.2% | $891.0M |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 11, 26 | Harczak Harry J Jr | director | S-Sale | 4,709 @ $38.18 | $179.8K |
| Sep 11, 26 | Harczak Harry J Jr | director | S-Sale | 2,123 @ $38.21 | $81.12K |
| May 19, 26 | Toomey John M | director | 0 | — | |
| May 19, 26 | Harczak Harry J Jr | director | A-Award | 1,873 @ $50.91 | $95.35K |
| May 19, 26 | Iriarte Esteban C | director | A-Award | 1,873 @ $50.91 | $95.35K |
| May 19, 26 | Williams Xavier | director | A-Award | 1,873 @ $50.91 | $95.35K |
| Apr 3, 26 | Carlson Anthony J | director, officer: President and CEO | M-Exempt | 4,150 @ $48.00 | $199.2K |
| Apr 3, 26 | Carlson Anthony J | director, officer: President and CEO | F-InKind | 1,217 @ $48.00 | $58.42K |
